Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27426082 | 0.82 | POLB (0.71) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL1168754 | 0.79 | ALDH1A1 (0.63) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL21034352 | 0.79 | TAAR1 (0.59) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL1414871 | 0.79 | CA1 (0.67) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL4601440 | 0.79 | CA1 (0.59) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL4520702 | 0.79 | POLB (0.79) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL15672851 | 0.79 | MEN1 (0.58) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL12601599 | 0.79 | POLB (0.51) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL11103294 | 0.79 | CA1 (0.66) | PRMT1TAAR1HSD17B10GAAALDH1A1 | |
| SCHEMBL1156320 | 0.78 | CA12 (0.68) | ALDH1A1LMNACYP3A4POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0672036-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-09-20 | — | — | EP | claimed |
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| EP-1311475-B1 | AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7189756-B2 | Pyrrolidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | AEBI JOHANNES (CH) | 2004-12-02 | — | — | US | disclosed |
| US-6790860-B2 | USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| WO-2002008185-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001081322-A1 | NON-IMIDAZOLE BENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-0371253-B1 | Method and reagents for detecting amphetamine and/or d-methamphetamine in biological samples | ABBOTT LAB (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5262333-A | Fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0279213-B1 | FLUORESCENCE POLARIZATION IMMUNOASSAY FOR AMPHETAMINE/METHAMPHETAMINE | ABBOTT LABORATORIES (US) | 1992-10-21 | — | — | EP | disclosed |
| US-4952336-A | USING TWO FLUORESCEIN TRACER DERIVATIVES | ABBOTT LABORATORIES (US) | 1990-08-28 | — | — | US | disclosed |
| EP-0371253-A2 | Method and reagents for detecting amphetamine and/or d-methamphetamine in biological samples | ABBOTT LABORATORIES (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4868132-A | BINDING TO A FLUORESCEIN TYPE TRACER, PRETREATMENT WITH PERIODATE | ABBOTT LABORATORIES (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0279213-A1 | Fluorescence polarization immunoassay for amphetamine/methamphetamine | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | PRMT1 1751/4885TAAR1 3875/4885HSD17B10 39/4885 |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | MMP1, PEPD, MMP25 | PRMT1 234/4885TAAR1 3619/4885HSD17B10 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.